Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Oct-Dec;80(4):923-40.
doi: 10.3797/scipharm.1206-12. Epub 2012 Aug 6.

Simultaneous Determination of Atorvastatin and Aspirin in Human Plasma by LC-MS/MS: Its Pharmacokinetic Application

Affiliations

Simultaneous Determination of Atorvastatin and Aspirin in Human Plasma by LC-MS/MS: Its Pharmacokinetic Application

Ramakrishna Gajula et al. Sci Pharm. 2012 Oct-Dec.

Abstract

A simple, rapid, and sensitive liquid chromatography tandem mass spectro-metric (LC-MS/MS) assay method has been developed and fully validated for the simultaneous quantification of atorvastatin and aspirin in human plasma using a polarity switch. Proguanil and furosemide were used as the internal standards for the quantification of atorvastatin and aspirin, respectively. The analytes were extracted from human plasma by the liquid-liquid extraction technique using methyl tert-butyl ether. The reconstituted samples were chromatographed on a Zorbax XDB Phenyl column by using a mixture of 0.2% acetic acid buffer, methanol, and acetonitrile (20:16:64, v/v) as the mobile phase at a flow rate of 0.8 mL/min. Prior to detection, atorvastatin and aspirin were ionized using an ESI source in the multiple reaction monitoring (MRM) mode. The ions were monitored at the positive m/z 559.2→440.0 transition for atorvastatin and the negative m/z 179.0→136.6 transition for aspirin. The calibration curve obtained was linear (r(2) ≥ 0.99) over the concentration range of 0.20-151 ng/mL for atorvastatin and 15.0-3000 ng/mL for aspirin. The method validation was performed as per FDA guidelines and the results met the acceptance criteria. A run time of 3.0 min for each sample made it possible to analyze more than 300 human plasma samples per day. The proposed method was found to be applicable to clinical studies.

Keywords: Acetylsalicylic acid; Aspirin; Atorvastatin; Chromatography; Liquid–liquid extraction; Pharmacokinetics.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Chemical structures of atorvastatin, aspirin, proguanil, and furosemide.
Fig. 2.
Fig. 2.
Typical MRM chromatograms of atorvastatin (left panel) and IS (right panel) in (A) human blank plasma; (B) human plasma spiked with IS; (C) an LLOQ sample along with IS; and (D) a 1.5 h plasma sample (10.1 ng/mL) showing atorvastatin peak along with IS obtained following oral administration of 20 mg of atorvastatin tablet to a healthy volunteer.
Fig. 3.
Fig. 3.
Typical MRM chromatograms of aspirin (left panel) and IS (right panel) in (A) human blank plasma; (B) human plasma spiked with IS; (C) an LLOQ sample along with IS; and (D) a 1.5 h plasma sample (304 ng/mL) showing aspirin peak along with IS obtained following oral administration of 75 mg of aspirin tablet to a healthy volunteer.
Fig. 4.
Fig. 4.
Mean plasma concentration–time profile of atorvastatin (A) and aspirin (B), in human plasma following oral dosing of atorvastatin (20 mg) and aspirin (75 mg) tablet to healthy volunteers (n = 6).

Similar articles

Cited by

References

    1. Jain KS, Kathiravan MK, Somani RS, Shishoo CJ. The biology and chemistry of hyperlipedemia. Bioorg Med Chem. 2007;15:4674–4699. http://dx.doi.org/10.1016/j.bmc.2007.04.031. - DOI - PubMed
    1. Kannel WB. Risk stratification in hypertension: new insights from the Famingham Study. Am J Hypertens. 2000;1:3S–10S. http://dx.doi.org/10.1016/S0895-7061(99)00252-6. - DOI - PubMed
    1. Davidson MH, Toth PP. Comparative effects of lipid–lowering therapies. Prog Cardiovasc Dis. 2004;47:73–104. http://dx.doi.org/10.1016/j.pcad.2004.04.007. - DOI - PubMed
    1. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 1999;84:413–428. http://dx.doi.org/10.1016/S0163-7258(99)00045-5. - DOI - PubMed
    1. Bakker–Arkema RG, Davidson MH, Goldstein RJ, Davignon RJ, Isaacsohn SL, Weiss SR, Keilson LM, Brown MV, Miller VT, Shurzinske LJ. Efficiency and safety of a new HMG–CoA reductase inhibitor atorvastatin in patients with hypertriglyceridemia. JAMA. 1996;275:128–133. http://dx.doi.org/10.1001/jama.1996.03530260042029. - DOI - PubMed

LinkOut - more resources